Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 0,38 M
EBIT 2015 -38,9 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,59 M
EBIT 2016 -38,8 M
Net income 2016 -35,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 221x
Capi. / Sales 2016 141x
Capitalization 83,9 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 10:30amShareholder meeting
More about the company
Latest news on CEL-SCI CORPORATION
05/22 CEL SCI : Secures OK to Conduct Its Phase 3 Multikine Trial in Italy
05/21 CEL SCI : NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock a..
05/21 CEL SCI : Announces Proposed Public Offering of Common Stock and Warrants
05/20 CEL SCI : Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
05/18 CEL SCI : Gets OK to Conduct Its Phase 3 Multikine Trial in Italy
05/14 CEL SCI : Announces Proposed Public Offering of Common Stock
05/14 CEL SCI : Announces Proposed Public Offering of Common Stock
05/14 CEL SCI : Posts 2Q Fiscal Year 2015 Financial Results
More news
Sector news : Bio Therapeutic Drugs
05/24 QUINTILES TRANSNATIONAL : Launches New Solution to Meet Needs of Asia-Pacific Em..
05/22 SYNAGEVA BIOPHARMA : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investiga..
05/22 BLUEBIRD BIO : Announces Participation at the Jefferies 2015 Global Healthcare C..
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions